Freeze-Drying with Closed Vials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Freeze-Drying with Closed Vials
The authors present an aseptic-filling process for freeze-dried liquids using the closed-vial technology.


Pharmaceutical Technology


Process qualification


Figure 4: Lyophilization unit loaded with closed vials; lyophilized products inside closed vials. (ALL FIGURES ARE COURTESY OF THE AUTHORS.)
To ensure that Crystal technology is suitable for lyophilization, several tests have been conducted using various products, quantities, and conditions. For example, the authors:
  • Used various excipients to investigate lyophilization feasibility: qualification started with an easily lyophilized excipient (lactose 5%) and finished with a complex one (glass transition point below –38 C).
  • Increased vial quantities per lyophilization cycle: starting with a few vials and using glass vials as a control, lyophilization cycles were made with up to 720 vials placed on two shelves (see Figure 4).
  • Used sensitive products to assess the quality of the lyophilization process for the product. (Living viruses that are particularly sensitive to lyophilization have been used to assess the recovery after lyophilization).

All tests were performed in a Christ Epsilon 2.25 D freeze dryer with seven shelves and an industrial controlling system, using 2-mL closed vials (22.25-mm diameter) and penetrators molded in high-density polyethylene, from a two-cavity mold.

Closure integrity after laser resealing has been tested, as has effective protection of the plastic cap. The following aspects were observed and analyzed for most cycles:
  • Correct lift-back of pushers at time of shelf's upward movement at the end of the cycle.
  • Quality of the closure integrity after resealing.
  • Humidity content of cakes (target is 1%, +/- 0.2%).
  • Visual aspect of cakes.
  • For viruses, content titer was measured at cycle end and after accelerated aging (seven days at 37 C), compared with lyophilized glass vials. In some cycles, temperature was recorded with probes installed in plastic vials and in control glass vials to analyze temperature curves.

The outcomes of these tests were:

  • Closed vials and their closure integrity remain unaffected after undergoing temperature and pressure cycles of a freeze-drying cycle.
  • Plastic material and elevated bottom of the vial are not deterrent to effective energy transfers. It is likely that the combination of a continuous pressure over the vial top applied by the upper shelf during the complete cycle and a perfectly flat vial bottom help the contact between the vial and the shelves and therefore the conductive part of the heat exchange process.
  • Cycle is extended by 20 min during the first phase of freezing, right after the change of phase and temperature uplift. However, the same terminal temperature (–55 C) is reached in the same manner at the end of the freezing phase.
  • All tests are successful even for most complex excipients when similar cycles are used compared with a glass vial (2-mL vial).
  • Highly sensitive viruses are recovered with similar titers in Crystal and glass vials when both are being processed together in the same cycle.
  • To ensure that the vial is effectively self-resealed after the cycle, high negative pressure inside the vial at exit of the chamber is not recommended.

Conclusion

The ready-to-fill closed vial used for liquid products is suitable for freeze-drying without modification. It also holds substantial containment and functional advantages over the glass vial. This vial is suitable for classical freeze dryers with minimal impact on cycles. Even though the quality of the lyophilized product in a ready-to-fill closed vial remains at same level as a lyophilized product in a glass vial, the ready-to-fill closed vial process is easier and product sterility assurance is at a higher level. Useful for all kinds of products, freeze-drying in a plastic, closed vial brings additional definitive benefits to both the patient, the healthcare specialist, and the manufacturer when product containment is mandatory such as with cytotoxic and biohazard products.

References

1. B. Verjans, J. Thilly, and C. Vandecasserie, "A New Concept in Aseptic Filling: Closed-Vial Technology," Pharm. Technol., Aseptic Processing supplement, s24–s29 (2005).

2. J. Thilly, D. Conrad, and C. Vandecasserie, "Aseptic Filling of Closed, Ready-to-Fill Containers," Pharm. Eng., 26 (2), 66–74 (2006).

Acknowledgments

The authors would like to thank Romain Veillon at Glaxo-SmithKline Biologicals for his supportive contribution to the experimental tests as well as his technical expertise and advice. Aseptic Technologies benefits from grants from the Walloon Region and the Agence Wallone L'Exportation (AWEX). Core closed-vial technology has been licensed by Medical Instill Technologies.

Jacques Thilly* is director of research and development at Aseptic Technologies, Rue Camille Hubert 7-9, B-5032 Gembloux, Belgium, tel. +32 81 409 413, fax +32 81 409 411,
Yves Mayeresse is senior manager and head of freeze-drying at GlaxoSmithKline Biologicals.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here